Werewolf Therapeutics (HOWL) Enterprise Value (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Enterprise Value of -$22.0 million for Q2 2026, up 71.65% year-over-year from -$12.8 million in Q2 2025, and up 52.69% on a QoQ basis from -$46.5 million in Q1 2026.
Werewolf Therapeutics (HOWL) Enterprise Value (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$22.0 million in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$22.0 million, up 71.65% year-over-year; the trailing twelve-month figure through Jun 2026 was -$22.0 million (up 71.65% YoY), and the FY2025 annual result was -$57.0 million, up 48.6% from the prior year.
- Enterprise Value rose to -$22.0 million in Q2 2026, from -$46.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$22.0 million in Q2 2026 and troughed at -$147.9 million in Q1 2023.
- A 5-year average of -$109.9 million and a median of -$129.7 million in 2022 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2022, when Enterprise Value slumped 69.87%; it then surged 71.65% in 2026.
- A 5-year view of Enterprise Value shows it stood at -$129.3 million in 2022, then declined by 3.89% to -$134.3 million in 2023, then gained by 17.38% to -$111.0 million in 2024, then surged by 48.6% to -$57.0 million in 2025, then soared by 61.44% to -$22.0 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$22.0 million in Q2 2026, -$46.5 million in Q1 2026, and -$57.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Werewolf Therapeutics | 20.90 Mn | 20.90 Mn | - | -22.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.00 Mn |
| Mar 31, 2026 | -46.50 Mn |
| Dec 31, 2025 | -57.05 Mn |
| Sep 30, 2025 | -65.71 Mn |
| Jun 30, 2025 | -77.60 Mn |
| Mar 31, 2025 | -92.04 Mn |
| Dec 31, 2024 | -111.00 Mn |
| Sep 30, 2024 | -122.83 Mn |
| Jun 30, 2024 | -135.30 Mn |
| Mar 31, 2024 | -139.19 Mn |
| Dec 31, 2023 | -134.34 Mn |
| Sep 30, 2023 | -130.06 Mn |
| Jun 30, 2023 | -137.45 Mn |
| Mar 31, 2023 | -147.87 Mn |
| Dec 31, 2022 | -129.32 Mn |
| Sep 30, 2022 | -140.45 Mn |
| Jun 30, 2022 | -145.71 Mn |
| Mar 31, 2022 | -143.71 Mn |
| Dec 31, 2021 | -157.53 Mn |
| Sep 30, 2021 | -170.44 Mn |